

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Netrin 1 (NTN1); unc-5 homolog A (<i>Caenorhabditis elegans</i>) (UNC5A; UNC5H1); UNC5B (UNC5H2)	<p>Studies in primary tumors, in cell cultures and in mice suggest that targeting interactions between NTN1 and UNC5H could help treat NSCLC.</p> <p>In an NSCLC cell line with high levels of NTN1 expression, NTN1 inhibition induced apoptosis.</p> <p>In xenograft mice bearing NSCLC tumors with high levels of NTN1 expression, NTN1 inhibition led to lower tumor growth and greater tumor necrosis compared with what was seen in xenograft mice bearing NSCLC tumors expressing low levels of NTN1. Ongoing work is examining NTN1 expression in additional types of NSCLC.</p> <p>Netris Pharma is developing leads that target NTN1-UNC5H interactions.</p>	Patented; exclusively out-licensed to Netris Pharma	<p>Delloye-Bourgeois, C. <i>et al.</i> <i>J. Natl. Cancer Inst.</i>; published online Feb.10, 2009; doi:10.1093/jnci/djn491</p> <p>Contact: Patrick Mehlen, University of Lyon, Lyon, France e-mail: mehlen@lyon.fnclcc.fr</p>
		<p>SciBX 2(7); doi:10.1038/scibx.2009.269 Published online Feb. 19, 2009</p>		